Instrumentation Laboratory S.P.A.

Instrumentation Laboratory S.P.A., an Italy-based medical diagnostics company headquartered in Milan, supplies blood bank reagents, blood gas analyzers, and diagnostic screening equipment to the U.S. Department of Defense and military healthcare system as a prime contractor competing on full-and-open (non-set-aside) delivery orders and indefinite delivery contracts. The vendor has been a registered federal contractor since 2003 and operates exclusively as a prime, with no subcontract footprint across the visible federal award base.

Instrumentation Laboratory's capability portfolio centers on four product lines: PANOSCREEN I, II, and III medical screening equipment; GEM PREMIER 5000 PAK (31D) blood gas analyzers and reagents; blood bank reagents including Immucor products; and full-risk maintenance services for deployed diagnostic equipment. The vendor's concrete federal work includes a $29,025 delivery order from the Defense Health Agency for blood bank reagents (April 2026, completion February 2027), a $44,595 delivery order from the Navy Bureau of Medicine and Surgery for GEM PREMIER 5000 PAK devices (September 2023), a $22,839 full-risk maintenance service contract with the Defense Health Agency (September 2023, completion September 2026), and a $160,000 single-award indefinite delivery contract with the Defense Health Agency for blood bank reagents supporting Naval Medical Readiness Training Center Sigonella (February 2026, completion February 2031).

Customer concentration is heavily weighted toward naval and military healthcare. The top five customer entities account for 85% of recent awards by count. The Navy Bureau of Medicine and Surgery dominates both volume (34 awards, $1.4 million combined potential value) and dollar value, followed by the Defense Health Agency (12 awards, $443 thousand) and the Department of the Army (18 total awards across multiple sub-entities, $88 thousand combined). The vendor serves ten distinct federal customer agencies, but naval medical readiness is the primary driver. The vendor holds three active indefinite delivery contracts: a $178,382 single-award IDC with the Navy Bureau of Medicine and Surgery for GEM PREMIER 5000 PAK (31D) through September 2026; a $140,572 single-award IDC with the Defense Health Agency for PANOSCREEN equipment through January 2030; and a $160,000 single-award IDC with the Defense Health Agency for blood bank reagents through February 2031. Five delivery orders have been placed under the N6817125D2002 PANOSCREEN IDC ($38 thousand combined potential value), and ten delivery orders under the Army's W912PF07A0002 indefinite delivery contract ($8 thousand combined potential value).

Activity has been episodic. Awards per year averaged one to two through 2023, then expanded to six awards in 2025 before contracting to three in 2026 year-to-date. The vendor faces minimal near-term recompete exposure — only three awards (combined potential value $94 thousand) complete within the next twenty-four months. All work is performed at the contractor's Italy-based location. The vendor's award portfolio tracks NAICS 336413 (In-Vitro Diagnostic Substance Manufacturing) and PSC 6625 (In Vitro Diagnostic Substances, Reagents, Test Kits and Sets) as the primary category concentrations, reflecting its role as a specialized medical diagnostics supplier rather than a broad-based defense contractor.